June 26 (Reuters) - Prima Biomed Ltd PRR.AX
* Operational update
* Says is pleased to advise that clinical studies of IMP321 are progressing well
* Says final results of 15 patients from safety run-in phase of aipac are expected in q4 of 2017
* Says data from three cohorts related to the tacti-mel trial is expected in h1 2018 Source text for Eikon: ID:nGNXNYPICa Further company coverage: PRR.AX